Copyright
©The Author(s) 2021.
World J Hepatol. Mar 27, 2021; 13(3): 362-374
Published online Mar 27, 2021. doi: 10.4254/wjh.v13.i3.362
Published online Mar 27, 2021. doi: 10.4254/wjh.v13.i3.362
Univariate analysis | Multivariate analysis1 | |||
P value | HR (95%CI) | P value | HR (95%CI) | |
Age of donor ≥ 70 years | 0.55 | 0.73 (0.26-2.05) | ||
Recipient | ||||
Liver steatosis | 0.1 | 0.408 (0.09-1.79) | ||
Age ≥ 60 years | 0.94 | 1.04 (0.39-2.78) | ||
HCV infection as cause of liver disease | 0.02 | 3.02 (1.17-7.81) | 0.003 | 4.94 (1.72-14.17) |
Presence of hepatocellular carcinoma | 0.57 | 1.31 (0.52-3.34) | ||
MELD score ≥ 20 | 0.02 | 3.16 (1.12-8.91) | 0.003 | 6.06 (1.88-19.56) |
Diabetes before transplantation | 0.63 | 1.32(0.43-4.01) | ||
Hypertension before transplantation | 0.05 | 2.78 (0.98-7.90) | - | - |
MDRD-4 at baseline | 0.35 | 0.99 (0.97-1.01) | ||
Mycophenolate mofetil at initial therapy | 0.89 | 1.07 (0.38-3.02) | ||
Outcomes and complications | ||||
BPAR | 0.20 | 2.08 (0.67-6.43) | ||
Arterial complications | 0.06 | 2.91 (0.94-9.06) | 0.03 | 3.76 (1.12-12.62) |
Biliary complications | 0.59 | 1.41 (0.40-4.92) | ||
Renal dysfunction early after transplant2 | 0.08 | 2.40 (0.90-6.38) | - | - |
Renal hypertension | 0.82 | 1.12 (0.42-3.02) | ||
De novo diabetes | 0.02 | 3.25 (1.24-8.55) | - | - |
Cardiovascular | 0.14 | |||
Arterial hypertension | 0.08 | 0.32 (0.09-1.15) | - | - |
Heart failure | 0.26 | 0.31 (0.04-2.37) | ||
De novo tumor | 0.005 | 4.20 (1.56-11.32) | < 0.001 | 13.82 (4.06-46.98) |
HCV recurrence | 0.22 | 1.79 (0.70-4.53) | ||
HCC recurrence | 0.008 | 16.61 (2.10-131.07) | - | - |
Any infection | 0.71 | 1.12 (0.47-3.03) | ||
Bacterial infection | 0.04 | 2.71 (1.04-7.07) | - | - |
Viral infection | 0.39 | 0.61 (0.20-1.87) | ||
Fungal infection | 0.87 | 1.19 (0.16-9.03) | ||
Cytomegalovirus infection | 0.79 | 0.86 (0.28-2.62) | ||
Normal renal function at last visit (MDRD-4 ≥ 60 mL/min/1.73 m2) | 0.92 | 1.08 (0.23-5.08) | ||
Mean tacrolimus levels at days 1-30 after LT | ||||
> 10 ng/mL vs ≤ 10 ng/mL | 0.44 | 1.44 (0.57-3.65) | ||
< 7 ng/mL (reference)3 | 0.32 | |||
7-10 ng/mL | 0.31 | 0.49 (0.12-1.96) | ||
> 10 ng/mL | 0.59 | 1.33 (0.47-3.73) | ||
> 8 ng/mL vs < 8 ng/mL3 | 0.78 | 1.14 (0.44-2.95) | ||
Early graft dysfunction | 0.08 | 2.44 (0.890-6.63) | < 0.001 | 6.02 (2.34-15.49) |
- Citation: Gastaca M, Ruiz P, Bustamante J, Martinez-Indart L, Ventoso A, Fernandez JR, Palomares I, Prieto M, Testillano M, Salvador P, Senosiain M, Suárez MJ, Valdivieso A. Early tacrolimus exposure does not impact long-term outcomes after liver transplantation. World J Hepatol 2021; 13(3): 362-374
- URL: https://www.wjgnet.com/1948-5182/full/v13/i3/362.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i3.362